NovoCure (NASDAQ:NVCR - Get Free Report) announced its earnings results on Thursday. The medical equipment provider reported ($0.61) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.27), Zacks reports. NovoCure had a negative return on equity of 41.48% and a negative net margin of 25.93%.
NovoCure stock traded down $2.73 during midday trading on Thursday, hitting $19.23. 2,803,360 shares of the stock were exchanged, compared to its average volume of 1,243,278. The company has a quick ratio of 1.44, a current ratio of 1.49 and a debt-to-equity ratio of 0.27. NovoCure has a 52 week low of $11.70 and a 52 week high of $34.13. The company has a fifty day simple moving average of $25.81 and a two-hundred day simple moving average of $21.41. The stock has a market capitalization of $2.08 billion, a PE ratio of -13.74 and a beta of 0.62.
NVCR has been the subject of several research reports. Evercore ISI upgraded shares of NovoCure from an "in-line" rating to an "outperform" rating and raised their price objective for the company from $18.00 to $30.00 in a research report on Monday, December 2nd. Piper Sandler raised their target price on shares of NovoCure from $28.00 to $42.00 and gave the company an "overweight" rating in a research note on Friday, December 13th. Wedbush reaffirmed a "neutral" rating and issued a $29.00 target price on shares of NovoCure in a research note on Monday, January 13th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $38.00 target price on shares of NovoCure in a research note on Tuesday, January 14th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $32.67.
Get Our Latest Research Report on NovoCure
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider NovoCure, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NovoCure wasn't on the list.
While NovoCure currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.